Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 22 studies | 70% ± 20% | |
lung | 19 studies | 52% ± 21% | |
intestine | 13 studies | 39% ± 18% | |
kidney | 9 studies | 51% ± 26% | |
liver | 6 studies | 38% ± 12% | |
brain | 6 studies | 49% ± 29% | |
bone marrow | 6 studies | 49% ± 28% | |
lymph node | 6 studies | 66% ± 26% | |
uterus | 6 studies | 38% ± 12% | |
prostate | 4 studies | 30% ± 9% | |
breast | 4 studies | 44% ± 14% | |
heart | 3 studies | 17% ± 1% | |
adipose | 3 studies | 43% ± 20% | |
adrenal gland | 3 studies | 47% ± 27% | |
thymus | 3 studies | 42% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 65251.29 | 89 / 89 | 94% | 2256.14 | 843 / 901 |
breast | 100% | 69588.20 | 459 / 459 | 93% | 1462.94 | 1039 / 1118 |
thymus | 99% | 54137.29 | 648 / 653 | 93% | 1743.25 | 561 / 605 |
lung | 100% | 135500.77 | 578 / 578 | 92% | 1930.25 | 1060 / 1155 |
uterus | 95% | 32170.99 | 161 / 170 | 80% | 1458.74 | 368 / 459 |
prostate | 98% | 34392.61 | 240 / 245 | 77% | 599.28 | 386 / 502 |
intestine | 90% | 46604.12 | 874 / 966 | 78% | 1040.47 | 409 / 527 |
esophagus | 88% | 23460.73 | 1269 / 1445 | 75% | 875.60 | 138 / 183 |
stomach | 84% | 28977.03 | 303 / 359 | 79% | 1345.08 | 225 / 286 |
bladder | 86% | 26217.81 | 18 / 21 | 70% | 1026.32 | 352 / 504 |
skin | 70% | 22549.66 | 1271 / 1809 | 79% | 1929.58 | 372 / 472 |
adrenal gland | 97% | 54684.15 | 250 / 258 | 52% | 371.39 | 119 / 230 |
ovary | 48% | 9991.11 | 87 / 180 | 92% | 2078.19 | 397 / 430 |
pancreas | 32% | 6897.72 | 106 / 328 | 93% | 1493.99 | 165 / 178 |
liver | 41% | 7621.36 | 93 / 226 | 67% | 781.90 | 273 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 8106.06 | 29 / 29 |
spleen | 100% | 212376.49 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 100% | 78391.01 | 1200 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 126969.89 | 908 / 929 | 0% | 0 | 0 / 0 |
brain | 34% | 9684.62 | 888 / 2642 | 63% | 865.63 | 447 / 705 |
blood vessel | 93% | 42575.11 | 1236 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 2111.59 | 41 / 45 |
heart | 76% | 16292.63 | 658 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 44% | 609.56 | 35 / 80 |
muscle | 31% | 5040.40 | 245 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0032722 | Biological process | positive regulation of chemokine production |
GO_0048146 | Biological process | positive regulation of fibroblast proliferation |
GO_0001961 | Biological process | positive regulation of cytokine-mediated signaling pathway |
GO_0002606 | Biological process | positive regulation of dendritic cell antigen processing and presentation |
GO_0045657 | Biological process | positive regulation of monocyte differentiation |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0001516 | Biological process | prostaglandin biosynthetic process |
GO_1902166 | Biological process | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
GO_0019882 | Biological process | antigen processing and presentation |
GO_0051085 | Biological process | chaperone cofactor-dependent protein refolding |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0002906 | Biological process | negative regulation of mature B cell apoptotic process |
GO_0070206 | Biological process | protein trimerization |
GO_0002792 | Biological process | negative regulation of peptide secretion |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0031394 | Biological process | positive regulation of prostaglandin biosynthetic process |
GO_2000343 | Biological process | positive regulation of chemokine (C-X-C motif) ligand 2 production |
GO_0016064 | Biological process | immunoglobulin mediated immune response |
GO_0035691 | Biological process | macrophage migration inhibitory factor signaling pathway |
GO_0032757 | Biological process | positive regulation of interleukin-8 production |
GO_0030336 | Biological process | negative regulation of cell migration |
GO_0045060 | Biological process | negative thymic T cell selection |
GO_0045059 | Biological process | positive thymic T cell selection |
GO_2000448 | Biological process | positive regulation of macrophage migration inhibitory factor signaling pathway |
GO_0032755 | Biological process | positive regulation of interleukin-6 production |
GO_0043518 | Biological process | negative regulation of DNA damage response, signal transduction by p53 class mediator |
GO_0002286 | Biological process | T cell activation involved in immune response |
GO_0045581 | Biological process | negative regulation of T cell differentiation |
GO_0045582 | Biological process | positive regulation of T cell differentiation |
GO_0046598 | Biological process | positive regulation of viral entry into host cell |
GO_0001934 | Biological process | positive regulation of protein phosphorylation |
GO_0034341 | Biological process | response to type II interferon |
GO_0033674 | Biological process | positive regulation of kinase activity |
GO_0019883 | Biological process | antigen processing and presentation of endogenous antigen |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0030890 | Biological process | positive regulation of B cell proliferation |
GO_0060907 | Biological process | positive regulation of macrophage cytokine production |
GO_0090023 | Biological process | positive regulation of neutrophil chemotaxis |
GO_0006886 | Biological process | intracellular protein transport |
GO_0043030 | Biological process | regulation of macrophage activation |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0065003 | Biological process | protein-containing complex assembly |
GO_0045058 | Biological process | T cell selection |
GO_0050731 | Biological process | positive regulation of peptidyl-tyrosine phosphorylation |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0019886 | Biological process | antigen processing and presentation of exogenous peptide antigen via MHC class II |
GO_0002830 | Biological process | positive regulation of type 2 immune response |
GO_0005773 | Cellular component | vacuole |
GO_0030669 | Cellular component | clathrin-coated endocytic vesicle membrane |
GO_0032588 | Cellular component | trans-Golgi network membrane |
GO_0009986 | Cellular component | cell surface |
GO_0043202 | Cellular component | lysosomal lumen |
GO_0005634 | Cellular component | nucleus |
GO_0070062 | Cellular component | extracellular exosome |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0035692 | Cellular component | macrophage migration inhibitory factor receptor complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0030666 | Cellular component | endocytic vesicle membrane |
GO_0032991 | Cellular component | protein-containing complex |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005771 | Cellular component | multivesicular body |
GO_0005737 | Cellular component | cytoplasm |
GO_0012507 | Cellular component | ER to Golgi transport vesicle membrane |
GO_0035693 | Cellular component | NOS2-CD74 complex |
GO_0098553 | Cellular component | lumenal side of endoplasmic reticulum membrane |
GO_0042613 | Cellular component | MHC class II protein complex |
GO_0030658 | Cellular component | transport vesicle membrane |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0042658 | Molecular function | MHC class II protein binding, via antigen binding groove |
GO_0035718 | Molecular function | macrophage migration inhibitory factor binding |
GO_0019955 | Molecular function | cytokine binding |
GO_0050998 | Molecular function | nitric-oxide synthase binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0004896 | Molecular function | cytokine receptor activity |
GO_0042609 | Molecular function | CD4 receptor binding |
GO_0044183 | Molecular function | protein folding chaperone |
GO_0001540 | Molecular function | amyloid-beta binding |
GO_0023026 | Molecular function | MHC class II protein complex binding |
GO_0042289 | Molecular function | MHC class II protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CD74 |
Protein name | CD74 molecule HLA class II histocompatibility antigen gamma chain (HLA-DR antigens-associated invariant chain) (Ia antigen-associated invariant chain) (Ii) (CD antigen CD74) [Cleaved into: Class-II-associated invariant chain peptide (CLIP)] |
Synonyms | DHLAG |
Description | FUNCTION: Plays a critical role in MHC class II antigen processing by stabilizing peptide-free class II alpha/beta heterodimers in a complex soon after their synthesis and directing transport of the complex from the endoplasmic reticulum to the endosomal/lysosomal system where the antigen processing and binding of antigenic peptides to MHC class II takes place. Serves as cell surface receptor for the cytokine MIF.; FUNCTION: [Class-II-associated invariant chain peptide]: Binds to the peptide-binding site of MHC class II alpha/beta heterodimers forming an alpha-beta-CLIP complex, thereby preventing the loading of antigenic peptides to the MHC class II complex until its release by HLA-DM in the endosome. .; FUNCTION: [Isoform p41]: Stabilizes the conformation of mature CTSL by binding to its active site and serving as a chaperone to help maintain a pool of mature enzyme in endocytic compartments and extracellular space of antigen-presenting cells (APCs). Has antiviral activity by stymieing the endosomal entry of Ebola virus and coronaviruses, including SARS-CoV-2 . Disrupts cathepsin-mediated Ebola virus glycoprotein processing, which prevents viral fusion and entry. This antiviral activity is specific to p41 isoform . . |
Accessions | E7EQJ3 ENST00000523208.6 ENST00000009530.13 [P04233-1] ENST00000377795.7 [P04233-3] P04233 ENST00000353334.11 [P04233-2] ENST00000518797.6 ENST00000522246.5 H0YBZ8 H0YBZ2 |